Graeme Clark Institute for Biomedical Engineering
News and events
Tuesday 5:00 pm – 6:00 pmWhy is planning to prevent undesirable futures so difficult?Webinar
Wednesday 6:00–7:00 pmEngineering drug discovery: process and passionEvent
Thursday 6:00–7:30 pmMedical Bionics: A New Era in MedicineEvent
This year the HTIC is back and better than ever with the opportunity to share in $100k of Seed Funding.News
The ARC CMIT will train a new generation of industry-ready biomedical engineers with skills in personalised 3D printed medical implants.News
There were seven finalists pitching a range of medtech topics including health system platforms for managing diseases, musculoskeletal monitoring and 3D printed custom stents.News
The Graeme Clark Institute draws on the collective medical, engineering and scientific capabilities of the University of Melbourne, supported by healthcare and research partners from the Melbourne Biomedical Precinct and beyond.
Key areas of biomedical engineering expertise within the Institute include tissue engineering, nanomedicine, biomimetics, biomechanics, medical bionics, implant systems, biosignals, medical robotics, mechanobiology, computational engineering, systems and synthetic biology, biomedical imaging, and health informatics.
Neuro-electronics therapy and bionics
The translation of neural-electronic interface research into improved health outcomes is gathering pace, with advances in implantable miniaturised electronic devices that record or stimulate nerve signals.
Advances in 3D printing and the miniaturisation of devices are revolutionising medical technologies, providing the ability to personalise healthcare and improve the wellbeing of people around the world as never before.
Drug screening technologies and mechano-pharmacology
The field of ‘tissue-on-a-chip’ and ‘organ-on-a-dish’ is evolving rapidly and is opening opportunities in drug discovery, toxin screening and disease modelling.
The research focus of this program is in the area of kinematics and dynamics of robotics mechanisms (its modelling, analysis and manipulation) and their applications primarily in biomedical and clinical tasks.
Assistive and rehabilitation robotics
This project focuses on the study of robotics technology in the investigating human motor systems and the clinical rehabilitation of people with motion impairment, such as in post-stroke patients.
Technologies for the management of Parkinson’s Disease
The research is focussed on the measurement movement disorders including Parkinson’s Disease (PD), to assist in their management
Biomaterials, bio-fabrication and regenerative medicine
The combination of materials science, materials engineering and clinical expertise is developing engineered tissues to replace or support the repair of natural tissue.
Computational modeling for cardiovascular disease
Advances in cardiovascular and stent technology are providing new options to support the operation of cardiac systems, to monitor performance and to deliver medication.
Biomedical imaging technologies
Advanced imaging technologies will lead to improved diagnosis and treatment of a wide range of neurological disorders.
Nano-materials and drug-delivery systems
Novel nano-materials that interact with the body’s biological processes at the cellular level are providing new, targeted drug-delivery opportunities.
Fluid dynamic modelling for pharmaceutical manufacturing
The program is developing computational fluid dynamics models to understand and predict the behaviour of platelets in typical blood flow and during clotting.
Polymeric drugs for combating anti-microbial resistance
Nature’s prowess in making molecules with astounding properties, such as DNA, serves as important inspiration to Professor Greg Qiao.
Synthetic biology approaches to designer-stem-cell-based therapies
This research develops experimental and computational approaches to apply engineering design and analysis principles to study existing biological cellular systems and to create new cellular systems with user-defined properties and functions.
This program builds and analyses mathematical models of biological processes, pathways and networks, and the cellular geometries within which these processes take place.
Institute Director, Graeme Clark Institute
Director, Convergence Science Networks
Manager, Strategy, Graeme Clark Institute
Message from the director
The Graeme Clark Institute for Biomedical Engineering promotes and coordinates the extensive bioengineering activities that exist across The University of Melbourne, drawing on emerging scientific and engineering approaches to drive transformative clinical solutions.
The Graeme Clark Institute is located in the Melbourne Biomedical Precinct which has established itself as a major global research and teaching powerhouse, with over 25 collaborators from health services, research and academic partners. The Graeme Clark Institute is at the centre of this precinct, and has unparalleled access to the clinical and research opportunities available across the entire network of partners. The strength of these partners, the relationships and existing collaborations, together with the proximity of the facilities provides unique opportunities to develop transformative health technologies.
By creating a community of engineers, scientists and clinicians in the healthcare system, relevant clinical problems will be identified and strategies for new approaches will be enabled and developed in partnership with industry.
Professor Mark Cook
Director, Graeme Clark Institute
To find out our aims, and organisational and governance structure, visit:
The Graeme Clark Institute partners with healthcare and research organisations, industry and government to solve today’s challenges and develop new technologies for tomorrow. We work with our partners to translate research into innovations that leads to improved health outcomes.
Centres and institutes contributing to research in biomedical engineering at the Graeme Clark Institute include:
- ARC Training Centre for Medical Implant Technologies
- ARC Training Centre in Cognitive Computing for Medical Technologies
- ARC Training Centre for Personalised Therapeutics Technologies
- Bionics Institute
- Melbourne Neuroscience Institute
- Bio21 Institute of Molecular Science and Biotechnology
- The Florey Institute of Neuroscience and Mental Health
- Aikenhead Centre for Medical Discovery
- Centre for Eye Research Australia
- Melbourne Academic Centre for Health
HealthTech Innovation Challenge 2020
Due to the ever evolving situation this year around COVID-19, there will be some changes to how the HealthTech Innovation Challenge will be run.
At this point in time, we cannot confirm what the pitching component of the challenge will look like, or the total amount of prize money to be distributed.
Please submit your EOI through the portal as we’d still love to support innovative HealthTech Projects in any way we can and we will be in touch with the latest on how things unfold.
2020 applications are now closed.
The Graeme Clark Institute for Biomedical Engineering (GCI) is inviting submissions for the HealthTech Innovation Challenge.
The objectives of the HealthTech Innovation Challenge are:
- To promote Science, Technology, Engineering, Mathematics and Medicine (STEMM)-based interdisciplinary research.
- To foster the translation of research with applications that will lead to improvements in health outcomes.
- To stimulate collaboration of MACH partner organisations.
Proposals must address the health technology (HealthTech) focus of the Challenge.
HealthTech refers to technology that is used to prevent, diagnose, monitor or treat diseases or medical conditions. HealthTech categories relevant to the Challenge are:
- Medical devices
- Assistive technology
- Hospital accessories, systems improvements and surgical instruments/tools
- Digital health including mobile health
- Technology that supports drug discovery and development, and pharmaceutical manufacturing.
2020 key dates
- Thursday 5 March
Launch date of the HealthTech Innovation Challenge
- Thursday 30 April
Application closing date
- Early May
Announcement of the finalists
- First week of June
Project start date
The submissions will be assessed against the following judging criteria.
The project demonstrates:
- A clear clinical need
- A concise, achievable project plan with realistic objectives
- Demonstrated efforts to conduct inter-disciplinary research, by team construction, partners or translation pathway
- Well placed research with significant potential for future funding by granting bodies and/or industry
The 2020 competition terms will be published here soon.
See the section on Application Process to accept the Competition Terms.
The Primary Investigator must ensure that the GCI contribution and support of the project be appropriately acknowledged in publications and presentations.
The four prizes are sponsored by the Graeme Clark Institute for Biomedical Engineering, The University of Melbourne.
- An application form
- A signed Letter of Support from the Chief Investigator (CI)’s host organisation executive or leadership team should be uploaded that states the Lead Investigator will bear full responsibility for the conduct of the project.
Within 24 hours of submission of application, the CI will receive an email from firstname.lastname@example.org confirming receipt of the application.
All enquiries should be made to email@example.com. The Subject line should state “HTIC 2020”.
Technology readiness levels
Technology readiness level (TRL) is an approach to assess the technology maturity and progress of the research activity. The TRL is defined below (U.S. Department of Defense, Technology Readiness Assessment Guidance, April 2011).
|TRL 1||Basic Research: Initial scientific research has been conducted. Principles are qualitatively postulated and observed. Focus is on new discovery rather than applications.|
|TRL 2||Applied Research: Initial practical applications are identified. Potential of material or process to solve a problem, satisfy a need, or find application is confirmed.|
|TRL 3||Critical Function or Proof of Concept Established: Applied research advances and early stage development begins. Studies and laboratory measurements validate analytical predictions of separate elements of the technology.|
|TRL 4||Lab Testing/Validation of Alpha Prototype Component/Process: Design, development and lab testing of components/processes. Results provide evidence that performance targets may be attainable based on projected or modelled systems.|
|TRL 5||Laboratory Testing of Integrated/Semi-Integrated System: System Component and/or process validation is achieved in a relevant environment.|
|TRL 6||Prototype System Verified: System/process prototype demonstration in an operational environment (beta prototype system level).|
|TRL 7||Integrated Pilot System Demonstrated: System/process prototype demonstration in an operational environment (integrated pilot system level).|
|TRL 8||System Incorporated in Commercial Design: Actual system/process completed and qualified through test and demonstration (pre-commercial demonstration).|
|TRL 9||System Proven and Ready for Full Commercial Deployment: Actual system proven through successful operations in operating environment, and ready for full commercial deployment.|